Preclinical and clinical studies have demonstrated efficacy combined with radiation, high-dose IL-2, and IL-10 through the expansion of CD8+ T cells against melanoma and renal cell carcinoma [31,32]. The gene discussed is CD8A; the disease is hereditary clear cell renal cell carcinoma.